Cargando…

Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty

BACKGROUND: Triptorelin, a long-acting gonadotropin-releasing hormone (GnRH) agonist, is available in 1-, 3-, and 6-month formulations to treat central precocious puberty (CPP). The triptorelin pamoate 22.5-mg 6-month formulation recently approved for CPP offers greater convenience to children by re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoo, Eunjoo, Kim, Sinae, Jung, Hye Lim, Shim, Jung Yeon, Shim, Jae Won, Kim, Deok Soo, Kwak, Ji Hee, Kim, Eun Sil, Yang, Aram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982112/ https://www.ncbi.nlm.nih.gov/pubmed/36875449 http://dx.doi.org/10.3389/fendo.2023.1134977

Ejemplares similares

Effect of gonadotropin-releasing hormone agonist treatment on near final height in girls with central precocious puberty and early puberty
por: Yang, Eun Hye, et al.
Publicado: (2023)

Central Precocious Puberty: Treatment with Triptorelin 11.25 mg
por: Chiocca, Elena, et al.
Publicado: (2012)

Use of the Subcutaneous Triptorelin Stimulation Test for Diagnosis of Central Precocious Puberty
por: Ahn, Jungmin, et al.
Publicado: (2023)

Gonadotropin-releasing Hormone Stimulation Test for Precocious Puberty
por: Kim, Han Kyul, et al.
Publicado: (2011)

Final height after gonadotropin-releasing hormone agonists with or without growth hormone in Korean girls with central precocious puberty and early puberty
por: Kwon, Eun Byul, et al.
Publicado: (2015)

Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone
por: Jung, Mo Kyung, et al.
Publicado: (2014)

Clinical data and basal gonadotropins in the diagnosis of central precocious puberty in girls
por: Durá-Travé, Teodoro, et al.
Publicado: (2021)

Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty
por: Lee, Hae Sang, et al.
Publicado: (2018)

Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study
por: Luo, Xiaoping, et al.
Publicado: (2023)

Effect of triptorelin 3.75 mg subcutaneously injection every 6 weeks on adult height in girls with idiopathic central precocious puberty
por: Liang, Yan, et al.
Publicado: (2015)

Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty
por: Cho, Ah Young, et al.
Publicado: (2023)

Effects of Gonadotropin-Releasing Hormone Agonist Therapy on Body Mass Index and Height in Girls with Central Precocious Puberty
por: Lee, Seung Jae, et al.
Publicado: (2012)

Effects of gonadotropin-releasing hormone agonist treatment on final adult height in boys with idiopathic central precocious puberty
por: Cho, Ah Young, et al.
Publicado: (2021)

Triptorelin stimulated luteinizing hormone concentrations for diagnosing central precocious puberty: study of diagnostic accuracy
por: Vukovic, Rade, et al.
Publicado: (2021)

Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy/tolerability comparison study
por: Valenzise, M., et al.
Publicado: (2023)

Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center
por: Chung, Lindsey Yoojin, et al.
Publicado: (2021)

Commentary on "Effect of gonadotropin-releasing hormone agonist treatment on near final height in girls with central precocious puberty and early puberty"
por: Kwon, Ahreum
Publicado: (2023)

Final height outcome of boys with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogue
por: Ma, Hua-mei, et al.
Publicado: (2013)

Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty
por: Swaiss, Hala H., et al.
Publicado: (2017)

Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty
por: Shim, Young Suk, et al.
Publicado: (2020)

Genetic factors in precocious puberty
por: Shim, Young Suk, et al.
Publicado: (2021)

SUN-063 Usefulness of a LHRH Test with Low Dose of Triptorelin Pamoate in the Diagnosis of Precocious Puberty in Girls
por: Llano, Juan Pablo, et al.
Publicado: (2020)

The effect of triptorelin and leuprolide on the level of sex hormones in girls with central precocious puberty and its clinical efficacy analysis
por: Wang, Lan, et al.
Publicado: (2021)

Leydig Cell Tumor-Induced Gonadotropin-Independent Precocious Puberty Progressing to Gonadotropin-Dependent Precocious Puberty Post Orchiectomy: Out of the Frying Pan Into the Fire
por: Singhania, Pankaj, et al.
Publicado: (2022)

Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty
por: Jeon, Min Jin, et al.
Publicado: (2021)

The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty
por: Kim, Sung Woo, et al.
Publicado: (2017)

Relationship between final adult height and birth weight after gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
por: Cho, Ah Young, et al.
Publicado: (2020)

Gonadotropin-Dependent Precocious Puberty: Neoplastic Causes and Endocrine Considerations
por: Stephen, Matthew D, et al.
Publicado: (2011)

The genes associated with gonadotropin-releasing hormone-dependent precocious puberty
por: Hwang, Jin Soon
Publicado: (2012)

Precocious puberty due to human chorionic gonadotropin secreting germinoma
por: Nascimento, Daiane J., et al.
Publicado: (2012)

Etiology and therapeutic outcomes of children with gonadotropin-independent precocious puberty
por: Kang, Eungu, et al.
Publicado: (2016)

The Gonadotropin-Releasing Hormone Analogue Therapy May Not Impact Final Height in Precocious Puberty of Girls With Onset of Puberty Aged 6 - 8 Years
por: Korkmaz, Ozlem, et al.
Publicado: (2019)

Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty
por: Kim, Eun Young
Publicado: (2015)

The characteristics of familial precocious puberty
por: Jeong, Hwal Rim, et al.
Publicado: (2015)

MON-241 Relationship between Final Height and Birth Weight after Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Central Precocious Puberty
por: Kim, Eun Young, et al.
Publicado: (2019)

Predicting the adult height of girls with central precocious puberty
por: Allali, Slimane, et al.
Publicado: (2011)

A diagnostic model of idiopathic central precocious puberty based on transrectal pelvic ultrasound and basal gonadotropin levels
por: Yuan, Bo, et al.
Publicado: (2020)

A Critical Appraisal of the Effect of Gonadotropin-Releasing Hormon Analog Treatment on Adult Height of Girls with Central Precocious Puberty
por: Bereket, Abdullah
Publicado: (2017)

Commentary on "Effects of gonadotropin-releasing hormone agonist treatment on final adult height in boys with idiopathic central precocious puberty"
por: Cheon, Chong Kun
Publicado: (2021)

Correction to: The Gonadotropin-Releasing Hormone Analogue Therapy May Not Impact Final Height in Precocious Puberty of Girls With Onset of Puberty Aged 6 - 8 Years
por: Korkmaz, Ozlem, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_smpe5ilu0fv4cvu4s4qeiscj2t